Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
Public Citizen, the consumer advocacy organization founded by Ralph Nader in 1971, published its July 2026 'Outrage of the Month' column titled 'The FDA, Peptides and RFK Jr.' The piece argues that when the FDA banned compounding of nineteen peptides in 2023, it cited immunogenicity risks for certain routes of administration, impurity concerns, and lack of sufficient information to know whether the drugs would cause harm when administered to humans. The advocacy position: 'There is no credible reason to believe that peptides deemed unproven or unsafe in 2023 are now miraculously safe and effective.' Public Citizen also raised concerns about the eight new PCAC panelists named Monday June 29, warning that the committee could be filled with members who would 'rubber stamp Kennedy's wishes' rather than substantively review the FDA staff briefing documents concluding the seven peptides have insufficient evidence for 503A bulks list eligibility. The piece adds to a June-July critic chorus that includes STAT News (panelist conflicts), NBC News + NPR + Washington Post (FDA scientists disagree with RFK Jr.), and BioCentury (peptide deregulation threatens drug-safety foundations).
BioCentury, the pharma-industry analyst publication, published a piece late in the week of June 29 arguing that HHS Secretary RFK Jr.'s peptide deregulation push threatens the foundations of drug safety. The industry-analyst framing adds to the growing critic chorus documenting concerns about the July 23-24 PCAC vote: FDA career-staff briefing documents concluding all seven peptides have insufficient evidence; STAT News' scoop on the panel-composition changes and conflicts of interest; NBC News, NPR, and Washington Post coverage of the FDA-staff-versus-RFK-Jr. tension; and Public Citizen's July 'Outrage of the Month' advocacy position. The specific BioCentury argument is that the drug-safety framework depends on FDA's ability to defer to career scientific staff on safety and evidence questions; a political override of the staff position (via new panelist composition or via FDA acceptance of a panel vote against staff) would establish a precedent applicable well beyond the seven peptides under immediate review. Additional voices: Personal Care Insights framed the deregulation as 'amid safety concern backlash'; the AP characterized the panel composition as a shift from 'academics and researchers' to 'health professionals who prescribe, produce or promote peptides.'
FDA career-staff scientists released their briefing documents for the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) meeting, concluding that none of the seven peptides under review (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence to support 503A bulks list eligibility. The briefing flagged four recurring concerns: limited or inadequate safety data; characterization and impurity concerns; lack of evidence of historical use in compounding meeting bulks-list criteria; and potential immunogenicity risk based on FDA adverse event data showing immune reactions to peptide preparations. The agency also presented data on product-quality failures observed in compounding-channel preparations, including heavy-metal contamination, microbial contamination, and mislabeled contents (some vials testing well below or above the labeled peptide concentration). The conclusion directly contradicts HHS Secretary RFK Jr.'s public position that the Category 2 removals (effective April 23, 2026) were meant to clear the path for 503A bulks list addition. Coverage ran across NBC News, NPR (syndicated to KPBS, Houston Public Media, WLRN, KGOU, HPPR, STLPR), Washington Post, and STAT News. The briefing is the most substantive regulatory development on the seven peptides since the April Federal Register notice.
STAT News reporter Lizzy Lawrence broke a scoop late Monday June 29, 2026 disclosing that the FDA on Monday published the names of eight new panelists who will serve on the July 23-24 Pharmacy Compounding Advisory Committee reviewing seven peptides for 503A bulks list eligibility. The majority of new members are involved with businesses that promote and prescribe peptides, meaning they will be weighing rules changes that could materially benefit them. Specific named members include Bobby Harshbarger, a pharmacist and Tennessee state senator whose mother Rep. Diana Harshbarger (R-TN) is also a pharmacist and has formally urged Kennedy to convene the panel; and Dr. Gabriel Alizaidy, who charges $500 for 'peptide and hormone' consultations that include advice on 'where to safely get each peptide or compound.' UC Davis cell-biology professor Paul Knoepfler told STAT: 'It's concerning that several members of the newly formulated [committee] appear to sell unproven offerings including stem cells and peptides, sometimes both.' FDA rules permit experts with financial stakes to serve on advisory panels as long as the relationship is disclosed and the agency explains why the expertise outweighs the potential conflict. Parallel coverage ran in CNN, PBS NewsHour, Washington Times, and CP24.
The Washington Post published a synthesis-explainer piece on June 30, 2026 titled 'Peptides are popular and controversial. Why?' walking consumers through the regulatory tension that has built up over the past month between HHS Secretary RFK Jr.'s public push to expand peptide access and FDA career-scientist briefing documents concluding the evidence is insufficient. The piece sits alongside the Post's parallel reporting (also June 30) titled 'RFK Jr.'s plan to boost peptide access just got more complicated' which framed the FDA staff recommendation as a substantive challenge to the Secretary's agenda. The two Post pieces target different audiences: the first is a consumer explainer (what peptides are, why wellness influencers tout them, what BPC-157 / TB-500 / MOTS-c actually do); the second is a politics-of-policy piece for the regulatory-and-policy audience. Both pieces frame the July 23-24 PCAC meeting as the substantive decision point, while the broader peptide-cultural-moment that the wellness market and STAT, NBC, and NPR coverage have all flagged forms the backdrop. The Washington Times, CNN, and PBS NewsHour ran adjacent coverage.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 closed at the end of business Tuesday June 30, 2026. Individuals or organizations who wanted to give a formal oral presentation at the public-comment portion of the meeting had to notify FDA by today with a brief description of the evidence or arguments to be presented, names and addresses of participants, in-person versus virtual preference, and a requested time allotment. Written comments to docket FDA-2025-N-6895 at regulations.gov remain open through July 9, 2026 for formal provision to PCAC members ahead of the meeting; the hard deadline for all written comments is July 22, 2026 at 11:59 PM ET. The two-day meeting at FDA's White Oak campus in Silver Spring, Maryland (with virtual attendance option) reviews seven peptides for 503A bulks list eligibility: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Oral-testimony filers will face the FDA career-staff briefing documents released this week concluding the evidence is insufficient on all seven substances.
STAT News' Pharmalittle column on Tuesday June 30, 2026 disclosed that US lawmakers are investigating whether several large pharmaceutical companies have been involved in clinical trials at Chinese sites that helped advance China's military capability. The investigation runs parallel to the BIOSECURE Act (passed 2024) restricting US biotech contracting with named Chinese CDMOs and gene-sequencing companies, and to the structural anxiety about Chinese scientific output that biotech executives flagged at BIO 2026 last week. The Insilico Medicine (Hong Kong-headquartered) + SK Biopharmaceuticals $2.5 billion AI-neuroimmune drug discovery pact announced June 22 at BIO 2026 opening sits inside this conversation, as do Chinese-API supply chains feeding US gray-market peptide vendors and the licensed-generic semaglutide flow from Indian and Chinese manufacturers post-March 2026 patent expiration. The lawmaker probe expands the regulatory aperture beyond the BIOSECURE Act's named-entity list toward broader scrutiny of US-China clinical-research cooperation. No specific drugmakers were publicly named in the Pharmalittle report.
The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026 at 11:59 PM ET. The proposal (Federal Register notice May 1, docket 2026-08552) cited 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. The final-comment filers split along expected lines. National Community Pharmacists Association (NCPA) and Alliance for Pharmacy Compounding (APC) argue for retention given continuing patient-access gaps for high-cost branded supply, particularly in rural and underserved markets where Hims & Hers and LifeMD telehealth penetration is lower. Partnership for Safe Medicines and the FDA's CDER drug safety arm support the exclusion, citing more than 455 adverse event reports linked to compounded semaglutide and 320+ reports tied to compounded tirzepatide as of early 2025, with a large fraction involving patient self-dosing errors from multidose vials. The FDA will publish its final determination in the Federal Register within several months of comment closure. Once finalized, large-scale compounded GLP-1 distribution through 503B outsourcing facilities ends; patient-specific 503A compounding may continue under narrow circumstances.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026 closes Tuesday June 30, 2026 — one day from this Monday digest. The two-day meeting at the FDA White Oak campus in Silver Spring, Maryland (with virtual attendance option) will vote on 503A bulks list eligibility for seven peptides: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Pharmacist-facing guidance in Pharmacy Times (Annie Lambert, PharmD, BCSCP, Wolters Kluwer clinical program manager for compliance solutions, published two days ago) advised compounding pharmacies to prepare for the post-PCAC market regardless of which specific peptides receive affirmative votes. Written comments to docket FDA-2025-N-6895 remain open through July 22 at 11:59 PM ET. The seven peptides came off the FDA's Category 2 'do not compound' list effective April 23, 2026; PCAC affirmative votes plus FDA acceptance are needed for formal 503A bulks list addition. Hims & Hers (HIMS), LifeMD, Henry Meds, and the broader telehealth-peptide platform space have priced in some affirmative outcomes (Barclays $39 HIMS PT, June 17; Leerink Market Perform reiteration this past week).
Pharmacy Times published an interview with Annie Lambert, PharmD, BCSCP, Wolters Kluwer's clinical program manager for compliance solutions, on Friday June 27, 2026, walking pharmacists through the operational response to the FDA's proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Three working points framed the guidance: the FDA's move signals a narrowing of large-scale compounding rather than an outright ban (503A pharmacies can still compound these agents under increased scrutiny); pharmacists should demonstrate fluency in the new regulatory rules and help patients weigh manufacturer-assistance programs (NovoCare $149-499/month, LillyDirect $299-449/month self-pay), direct-to-consumer channels, and the Medicare GLP-1 Bridge launching Wednesday July 1; patients should verify pharmacy licensure, question medication sourcing, and understand the distinction between FDA-approved branded products and compounded preparations. The guidance is the highest-profile professional-practice resource published in the comment-deadline week and is likely to circulate widely among the National Community Pharmacists Association and Alliance for Pharmacy Compounding memberships.
The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026, one day from this Sunday digest. The FDA proposed the exclusion on April 30 via a Federal Register notice published May 1 (docket 2026-08552), citing 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. Once the comment window closes and the FDA finalizes the determination, large-scale compounded GLP-1 distribution through 503B outsourcing facilities effectively ends. Patient-specific compounding through 503A pharmacies may continue under narrow circumstances (drug-shortage triggers, patient-specific clinical needs documented by the prescribing physician), but the bulk-compounding channel that supplied the 2022-2024 shortage-era compounded GLP-1 wave gets formally closed. The Partnership for Safe Medicines and FDA's CDER drug safety arm welcomed the proposal; compounding-pharmacy industry groups (APC, OFA) filed comments arguing for retention given continuing patient-access gaps for high-cost branded supply.
The week starting Monday June 29 stacks three federal regulatory milestones in three consecutive days. Monday: FDA's 503B GLP-1 exclusion public-comment window closes at 11:59 PM ET, finalizing the formal record on whether outsourcing facilities can continue compounding semaglutide, tirzepatide, and liraglutide. Tuesday June 30: registration for oral testimony at the July 23-24 Pharmacy Compounding Advisory Committee meeting closes (the meeting will vote 503A bulks list eligibility for BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon; the written-comment docket FDA-2025-N-6895 remains open through July 22). Wednesday July 1: the Medicare GLP-1 Bridge demonstration goes live for eligible Part D beneficiaries at $50/month for Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen), with Humana serving as single central processor for prior authorization, claims adjudication, and pharmacy payment. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Medicare Part D. The three cutoffs collectively reshape the GLP-1 access architecture: branded direct supply expands through Medicare, bulk compounding through 503B narrows, and the non-GLP-1 503A peptide question goes to PCAC.
Dr. Catherine Varney, the University of Virginia Health Obesity Medicine Director, gave WSET (Roanoke-Lynchburg ABC affiliate) a syndicated local-TV interview published June 25, 2026 walking through the clinical realities of the unregulated peptide market. Her position on BPC-157 and TB-500 (both under FDA Pharmacy Compounding Advisory Committee review on July 23, 2026): animal-study evidence shows promise, while human clinical evidence remains thin, and she will not prescribe them. The interview frames the distinction patients often miss: FDA-approved weight-loss medications such as Ozempic and Wegovy are synthetic GLP-1 receptor agonists with rigorous Phase 3 evidence and post-marketing safety surveillance, while BPC-157, TB-500, and the broader unregulated stack are research-chemical products with no completed Phase 3 trial in any human indication. Varney's quoted position: 'I will not prescribe them.' She added that she will instead monitor patients who choose to take them, watch their labs for adverse effects, and emphasize lifestyle interventions with long-standing evidence (eating better and exercising more). The story sits inside a broader pattern of academic-medical-center clinicians publishing consumer-facing warnings ahead of PCAC.
Medscape published 'Unapproved Retatrutide Use Challenges Clinicians' on Friday June 26, 2026, documenting the scale of gray-market and clinic-channel retatrutide use that runs parallel to Eli Lilly's Phase 3 TRIUMPH program. Two anchor data points: retatrutide exposures reported to US poison-control centers averaged 95 cases per month in Q1 2026, a 265% increase from the average across the last four months of 2025; and at least 50 US clinics staffed by licensed physicians and nurse practitioners openly advertise the unapproved drug to weight-loss patients. The piece frames the practical challenge for primary-care and obesity-medicine clinicians whose patients arrive already taking retatrutide sourced from research-chemical vendors, online clinics, or compounding pharmacies operating outside the FDA bulks-list framework. The Drug Topics companion story (same week) added that the prescribing rate is 'alarming' to obesity-medicine specialty groups. The data lands the same week as Senator Hassan's June 25 letter to HHS Secretary RFK Jr. demanding answers on the FDA-Lilly compassionate-use grant to a 79-year-old patient: one VIP-adjacent individual received the real drug through a sanctioned pathway while at least 50 clinics distribute the unregulated version at scale.
In addition to the political escalation (Senator Hassan's June 25 letter to RFK Jr.; Rep. Ted Lieu's June 24 terminal-illness press conference; White House counterattacks against STAT reporter Lizzy Lawrence and Lieu), STAT News reported that 18 bioethics experts, obesity-medicine clinicians, and current and former US government health officials told the outlet that Eli Lilly's decision to grant compassionate-use access to retatrutide for a single 79-year-old patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension 'struck them as unusual.' The core question raised by the bioethics community: why Lilly would offer compassionate use for a single patient when obesity is a population-scale condition affecting more than 100 million Americans, when expanded-access programs are typically structured around treatment INDs or intermediate-size protocols for broader access, and when the standard pathway for obesity-drug access is trial enrollment (TRIUMPH-2 obesity+T2D and TRIUMPH-3 obesity+CVD remain open). Jamy Ard (chief science officer, Advocate Health) said compassionate use is typically reserved for terminal illness. The bioethics critique is separate from the Trump-recipient speculation and is likely the more durable framing of the case as it moves through congressional oversight.
The Centers for Medicare & Medicaid Services' Medicare GLP-1 Bridge demonstration launches Wednesday July 1, 2026, five days from this digest's publication, providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen) for chronic weight management through December 31, 2027. Humana is the single central processor for prior authorization, claims adjudication, and pharmacy payment, operating outside of the standard Part D benefit's coverage and payment flow (Part D sponsors do not carry risk for eligible GLP-1 drugs under the Bridge). Two procedural details for prescribers: Medicare enrollment is not required to write a prescription or submit a prior-authorization request under the Bridge (the provider just cannot be on the Preclusion List), and prior-authorization requests will not be accepted or processed before July 1, when the prior-authorization form will be updated to include the fax submission number. Eligibility runs through three BMI tiers: BMI ≥35 with no additional requirement; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; or BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease. The Bridge bridges to the broader BALANCE Model launching January 2027 in Medicare Part D.
Senator Maggie Hassan (D-NH), ranking Democrat on the relevant committee, sent a formal written letter to HHS Secretary Robert F. Kennedy Jr. on June 25, 2026, demanding answers about whether President Trump (who turned 80 on June 14) is the 79-year-old patient who received compassionate-use access to Eli Lilly's investigational retatrutide. Hassan wrote: 'Reporting suggests that you have used this pathway to provide a highly anticipated medication for obesity to a single VIP individual for free, without providing that opportunity to other Americans.' Hassan also questioned Kennedy at a Senate committee hearing earlier the same day about 'vanity projects' at HHS. The June 25 letter is the first formal congressional action on the compassionate-use case originally reported by STAT News on June 23. Eli Lilly issued its first public statement to STAT News on June 25: 'We make these decisions following all applicable regulations.' The company has not disclosed how it evaluates retatrutide expanded-access requests or whether other applications are pending. Outside experts continue to question whether refractory obesity plus obstructive sleep apnea plus pulmonary hypertension meets the FDA's 'serious or immediately life-threatening' threshold typically reserved for terminal illness. The Senate letter creates an oversight track parallel to the political controversy already running through cable news and X.
California Rep. Ted Lieu (D) held a press conference on June 24, 2026 suggesting that President Trump canceled the signing of the bipartisan 21st Century ROAD to Housing bill earlier that day because he is fighting a terminal illness and dealing with side effects from an experimental drug. Lieu pointed to the STAT News retatrutide compassionate-use report and reasoned that compassionate-use access typically requires terminal illness. Lieu cited Trump being 'unable to stay awake at meetings, having visible arm weakness, and swelling in his hands' as supporting observations. White House Communications Director Steven Cheung responded by calling Lieu a 'dumba--' for the suggestion. The exchange escalated the political dimension of the retatrutide story from White House versus reporter (Kush Desai vs Lizzy Lawrence on June 23-24) to House Democrat versus White House Communications Director. The 21st Century ROAD to Housing Act is a bipartisan housing reform bill that Trump was scheduled to sign on Wednesday June 24, 2026, with the signing canceled the same day. The White House has not provided a public explanation for the cancellation beyond denying any connection to the retatrutide story.